U.S. Hospitality Stock News

What Golar LNG’s Recent Performance Tells You Golar LNG (GLNG) has been quietly moving on the radar of income and infrastructure focused investors, with the stock showing mixed short term returns but stronger gains over the past 3 months and past year. At a recent close of $43.23, Golar LNG sits against a backdrop of annual revenue of $393.522 million and net income of $65.676 million, tied to its floating liquefied natural gas operations and related shipping and regasification...

Contract renewal in the Caspian Sea puts Helmerich & Payne in focus Turan Drilling and Engineering, a joint venture involving Helmerich & Payne (HP) and bp, has secured a 5 year offshore operations and maintenance contract renewal covering 8 platforms in the Caspian Sea. See our latest analysis for Helmerich & Payne. HP's recent 5 year Caspian contract renewal comes alongside a 90 day share price return of 23.98% and a 1 year total shareholder return of 37.05%. This suggests momentum has been...

If you are wondering whether Primoris Services is still worth your attention after its strong run, or if the current share price is getting ahead of itself, this article is for you. The stock closed at US$151.99, with a 1 year return of 112.7% and a year to date return of 16.4%. This comes after a 7 day return showing an 8.3% decline and a flat 30 day result. Recent news flow around Primoris has focused on its position in capital projects and ongoing contract wins. This helps explain why the...

If you are wondering whether Enviri's share price still reflects fair value after its latest run, you are not alone. That is exactly what this breakdown will explore. The stock most recently closed at US$18.59, with returns of 3.9% year to date and 181.7% over the last year, even though the past week and month showed 3.9% and 1.2% declines. Recent coverage has focused on Enviri's repositioning as a standalone environmental services and solutions company and ongoing efforts to simplify its...

Alnylam Pharmaceuticals (ALNY) has been drawing interest after recent trading, with the share price around $331.24 and mixed short term returns, including a 7 day decline and a positive 1 day move. See our latest analysis for Alnylam Pharmaceuticals. That short term pullback, including a 6.6% 30 day share price return decline and a 26.6% 90 day share price return decline, sits against a much stronger backdrop. The 1 year total shareholder return is 39.7% and the 5 year total shareholder...

T-Mobile US (TMUS) is in the spotlight after launching the Samsung Galaxy S26 lineup with aggressive On Us promotions, exclusive 5G Advanced features, and bundled home internet deals aimed at both attracting and keeping customers. See our latest analysis for T-Mobile US. T-Mobile’s latest device promotions land as the share price sits at $213.15, with a 30-day share price return of 15.53% contrasting with a 1-year total shareholder return decline of 17.66%, while the 5-year total shareholder...

Venture Global stock reaction With no single headline event setting the agenda today, Venture Global (VG) is on investor radars largely because of its recent share performance and financial profile in the liquefied natural gas space. The stock last closed at $9.47, with a return of 1.7% over the past day and a negative 4.2% move in the past week. Performance over the past month and the past three months has been positive. See our latest analysis for Venture Global. VG's 90 day share price...

Stock performance snapshot and business context NIQ Global Intelligence (NIQ) has drawn attention after a recent 4.9% gain in a single session and an 8.4% move over the past week, following a weaker month and past 3 months. The company focuses on consumer intelligence through AI powered software and analytics that aggregate and enrich shopping data, giving consumer brands and retailers an omnichannel view of behavior across products, channels, and media. With reported revenue of US$4.1b and a...

Credo Technology Group Holding Ltd. recently announced a collaboration with AMD-only AI cloud provider TensorWave to deploy its ZeroFlap Active Electrical Cables and Optics, plus the PILOT telemetry platform, across TensorWave’s next-generation AI cluster infrastructure to boost reliability, uptime, and deployment speed. This deal underscores how Credo’s high-reliability interconnects and deep telemetry could become core building blocks in emerging AI cloud architectures. Now we’ll examine...

Netflix (NFLX) is back in focus after recent trading left the stock roughly flat over the past month but lower over the past 3 months and year, prompting investors to reassess its current valuation. See our latest analysis for Netflix. At a share price of US$84.59, Netflix has seen a 7.53% 7 day share price return alongside a 21.37% 90 day share price decline. Its 3 year total shareholder return of 168.39% contrasts with a 13.73% 1 year total shareholder return decline, which hints that...

Celsius Holdings (CELH) closed out FY 2025 with Q4 revenue of US$721.6 million and basic EPS of US$0.04, alongside trailing twelve month revenue of about US$2.5 billion and EPS of US$0.25. This provides a clear snapshot of where the business stands after a volatile year. The company reported quarterly revenue of US$332.2 million in Q4 2024 and US$721.6 million in Q4 2025, while EPS moved from a loss of US$0.09 to a profit of US$0.04 over the same period. This sets up a results season in which...

In February 2026, Repligen Corporation reported that fourth-quarter 2025 revenue rose to US$197.91 million from US$167.55 million a year earlier, swinging from a net loss to net income of US$13.29 million and turning prior per-share losses into positive earnings. Alongside this stronger profitability, the company issued relatively cautious 2026 guidance for revenue of US$810 million to US$840 million and diluted earnings per share of US$1.93 to US$2.01, which contrasted with its recent...

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...

If you are wondering whether Bilibili’s current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers actually say about value. Bilibili’s stock has been volatile, with a 7 day return of an 8% decline, a 30 day return of a 17.9% decline, but a 1 year return of 37.5% and a 3 year return of 32.0%. This gives mixed signals about how the market is currently pricing the business. Recent headlines around Bilibili have focused on its...

If you are wondering whether AbbVie’s current share price lines up with its underlying worth, you are not alone. This article is built to help you unpack that question clearly. AbbVie recently closed at US$224.69, with returns of 0.2% over the last week, 0.3% over the last month, a 2.0% decline year to date, and 13.3% over the past year, alongside longer term returns of 62.2% over 3 years and 157.5% over 5 years. Recent coverage around AbbVie has focused on its position as a large...

V2X, Inc. recently reported its full-year 2025 results, with revenue rising to US$4.48 billion and net income reaching US$77.88 million, alongside earnings guidance for 2026 and a place on the US$25 billion ATSP5 defense technology contract vehicle. Together with record quarterly revenue, major awards such as the T-6 aircraft program, and AI-focused partnerships, these updates underline V2X’s expanding role in high‑complexity defense support and modernization work. We’ll now examine how...

Vaxcyte stock overview after recent price move Vaxcyte (PCVX) has drawn fresh attention after its recent share move, with the stock last closing at $60. For investors, the key question is how this price lines up with the company’s current fundamentals. See our latest analysis for Vaxcyte. That latest move to $60 comes after a choppy stretch, with a 1 day share price return of a 4.82% decline but a 90 day share price return of 20.94%, while the 1 year total shareholder return sits at a 19.16%...

In February 2026, Microsoft’s latest earnings and disclosures showed AI and cloud-driven growth accompanied by sharply higher capital expenditures on data centers and infrastructure, while new partnerships, marketplace listings, and leadership changes in gaming underscored how deeply the company is embedding AI across its ecosystem. An important undercurrent is rising investor debate over whether Microsoft’s very large AI infrastructure outlays, extended depreciation schedules, and reliance...

John Deere and Bayer are partnering to launch wireless, integrated farm data transfer for U.S. growers. The connection links Bayer's FieldView platform with John Deere's Operations Center to move agronomic prescriptions directly to machines. The capability is planned to be available for the 2026 U.S. season, with global expansion expected after that. For Deere (NYSE:DE), this move adds another piece to its digital agriculture stack at a time when investors are already paying attention to...

If you are wondering whether Silicon Motion Technology is offering good value at its current price, you are not alone. The stock has drawn attention from investors trying to work out what a fair price really looks like. The share price closed at US$131.08 recently, with a 0.9% decline over the last 7 days but gains of 12.8% over 30 days, 39.8% year to date, 144.4% over 1 year, 109.4% over 3 years and 154.3% over 5 years. Those moves have kept the company on many investors' watchlists,...

AbCellera Biologics (ABCL) has drawn fresh attention after reporting a narrower quarterly loss than anticipated, supported by a substantial patent litigation settlement that lifted liquidity and coincided with progress across its clinical programs and manufacturing build out. See our latest analysis for AbCellera Biologics. The strong 1 day share price return of 12.54% and 7 day share price return of 11.49% around the results suggest investors are reassessing AbCellera’s risks and prospects...

DXP Enterprises (DXPE) has wrapped up FY 2025 with Q4 revenue of US$527.4 million and basic EPS of US$1.46, alongside net income excluding extraordinary items of US$22.8 million. On a trailing twelve month basis, revenue stands at about US$2.0 billion with EPS of US$5.65 and net income of US$88.6 million. The company has seen quarterly revenue move from US$470.9 million in Q4 2024 to US$527.4 million in Q4 2025, with basic EPS shifting from US$1.36 to US$1.46 over the same period. This puts...

Luckin Coffee (OTCPK:LKNC.Y) has wrapped up FY 2025 with fourth quarter revenue of about C¥12.8b and basic EPS of C¥1.62, rounding out a year in which trailing twelve month revenue reached roughly C¥49.3b and EPS came in at about C¥11.23. The company has seen quarterly revenue move from roughly C¥9.6b in Q4 2024 to C¥12.8b in Q4 2025, while basic EPS shifted from C¥2.64 to C¥1.62 over the same period, setting up a mixed picture that investors will likely weigh against the reported net income...

Earlier this week, Freddie Mac reported that the average 30-year fixed-rate mortgage fell to 5.98%, dropping below the 6% threshold for the first time since 2022. This move, paired with improving home availability, highlights how shifts in borrowing costs can quickly influence expectations for spring housing activity and mortgage demand. With mortgage rates dipping below 6%, we will explore how this development shapes Federal Home Loan Mortgage’s investment narrative and market...